Multiple Glioblastomas Ablation by Laser Interstitial Thermal Therapy (LITT): A Rare Case.

Multiple glioblastomas (GBMs) are aggressive, malignant, and sporadic brain tumors. We present the case of a 58-year-old patient with two GBMs in the right frontal lobe and associated edema. The patient presented with sudden left limb weakness accompanied by abnormal gait for five consecutive days. Magnetic resonance-guided laser interstitial thermal therapy (MRg-LITT), a minimally invasive technique that disperses thermal energy was used to cauterize the deep-seated brain lesions. Following two sessions of MRg-LITT, the patient showed full remission from symptoms. However, the disruption of the blood-brain barrier (BBB) induced vasogenic edema surrounding the necrotic GBMs. Post-operative nine-month MRI images revealed severe vasogenic edema and compression on the ventricles, shifting the midline toward the left side. Therefore the patient underwent an emergency craniectomy and continues to live with close follow-ups. Here, we established that LITT procedures were effective in cauterizing GBMs with no recurrence.

An Overview of MR-Guided Laser Interstitial Thermal Therapy (MRg-LITT) in Disrupting the Blood-Brain Barrier: Efficacy and Duration.

The blood-brain barrier (BBB) is a selectively semi-permeable layer, crucial in shielding the brain from external pathogens and toxic substances while maintaining ionic homeostasis and sufficient nutrient supply. However, it poses a significant challenge for drugs to penetrate the BBB in order to effectively target brain tumors. Magnetic resonance-guided laser interstitial thermal therapy (MRg-LITT) is a minimally invasive technique that employs thermal energy to cauterize intracranial lesions with the potential to temporarily disrupt the BBB. This further opens a possible therapeutic window to enhance patient outcomes. Here, we review the impact of MRg-LITT on BBB and blood tumor barrier (BTB) and the duration of the BBB disruption. Studies have shown that MRg-LITT is effective due to its minimally invasive nature, precise tumor targeting, and low complication rates. Although the disruption duration varies across studies, the average peak disruption is within the initial two weeks post-ablation period and subsequently exhibits a gradual decline. However, further research involving larger groups with extended follow-up periods is required to determine disruption duration more accurately. In addition, evaluating toxicity and glymphatic system disruption is crucial to circumvent potential risks associated with this procedure.